 SAN DIEGO, Aug. 26, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento announced today that it has notified The Texas AM University System TAMUS of its exercise of the option to an exclusive license for the global development and commercialization of highly potent main protease MPro inhibitors against SARS-CoV-2 and all current and emerging variants of concern VOCs. Sorrento and TAMUS previously announced the signing of the option agreement on August 24th and 25th, respectively: 